Poly Medicure Limited

NSEI:POLYMED 株式レポート

時価総額：₹254.5b

Poly Medicure マネジメント

マネジメント 基準チェック /24

Poly Medicureの CEO はHimanshu Baidで、 Sep1995年に任命され、 の在任期間は 29.33年です。 の年間総報酬は₹ 171.78Mで、 33.6%給与と66.4%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の11.59%を直接所有しており、その価値は₹ 29.51B 。経営陣と取締役会の平均在任期間はそれぞれ6.6年と8.6年です。

主要情報

Himanshu Baid

最高経営責任者

₹171.8m

報酬総額

CEO給与比率33.6%
CEO在任期間29.3yrs
CEOの所有権11.6%
経営陣の平均在職期間6.6yrs
取締役会の平均在任期間8.6yrs

経営陣の近況

Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Sep 20
Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Sep 22
Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Recent updates

Does Poly Medicure (NSE:POLYMED) Have A Healthy Balance Sheet?

Dec 28
Does Poly Medicure (NSE:POLYMED) Have A Healthy Balance Sheet?

With EPS Growth And More, Poly Medicure (NSE:POLYMED) Makes An Interesting Case

Dec 10
With EPS Growth And More, Poly Medicure (NSE:POLYMED) Makes An Interesting Case

Why Investors Shouldn't Be Surprised By Poly Medicure Limited's (NSE:POLYMED) 33% Share Price Surge

Nov 02
Why Investors Shouldn't Be Surprised By Poly Medicure Limited's (NSE:POLYMED) 33% Share Price Surge

Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Sep 20
Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Poly Medicure (NSE:POLYMED) Will Pay A Dividend Of ₹3.00

Sep 14
Poly Medicure (NSE:POLYMED) Will Pay A Dividend Of ₹3.00

After Leaping 41% Poly Medicure Limited (NSE:POLYMED) Shares Are Not Flying Under The Radar

Sep 06
After Leaping 41% Poly Medicure Limited (NSE:POLYMED) Shares Are Not Flying Under The Radar

Poly Medicure (NSE:POLYMED) Has A Pretty Healthy Balance Sheet

Aug 14
Poly Medicure (NSE:POLYMED) Has A Pretty Healthy Balance Sheet

Earnings Update: Here's Why Analysts Just Lifted Their Poly Medicure Limited (NSE:POLYMED) Price Target To ₹2,138

Jul 27
Earnings Update: Here's Why Analysts Just Lifted Their Poly Medicure Limited (NSE:POLYMED) Price Target To ₹2,138

Investors Still Waiting For A Pull Back In Poly Medicure Limited (NSE:POLYMED)

Jul 11
Investors Still Waiting For A Pull Back In Poly Medicure Limited (NSE:POLYMED)

Poly Medicure's (NSE:POLYMED) Promising Earnings May Rest On Soft Foundations

May 25
Poly Medicure's (NSE:POLYMED) Promising Earnings May Rest On Soft Foundations

Why You Should Care About Poly Medicure's (NSE:POLYMED) Strong Returns On Capital

May 12
Why You Should Care About Poly Medicure's (NSE:POLYMED) Strong Returns On Capital

Poly Medicure Limited's (NSE:POLYMED) Share Price Not Quite Adding Up

Mar 23
Poly Medicure Limited's (NSE:POLYMED) Share Price Not Quite Adding Up

Here's Why We Think Poly Medicure (NSE:POLYMED) Might Deserve Your Attention Today

Feb 15
Here's Why We Think Poly Medicure (NSE:POLYMED) Might Deserve Your Attention Today

Poly Medicure (NSE:POLYMED) Seems To Use Debt Quite Sensibly

Jan 16
Poly Medicure (NSE:POLYMED) Seems To Use Debt Quite Sensibly

Is Now The Time To Put Poly Medicure (NSE:POLYMED) On Your Watchlist?

Nov 14
Is Now The Time To Put Poly Medicure (NSE:POLYMED) On Your Watchlist?

Poly Medicure (NSE:POLYMED) Has More To Do To Multiply In Value Going Forward

Oct 24
Poly Medicure (NSE:POLYMED) Has More To Do To Multiply In Value Going Forward

Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Sep 22
Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Poly Medicure (NSE:POLYMED) Is Increasing Its Dividend To ₹3.00

Sep 08
Poly Medicure (NSE:POLYMED) Is Increasing Its Dividend To ₹3.00

Here's Why Poly Medicure (NSE:POLYMED) Can Manage Its Debt Responsibly

Aug 12
Here's Why Poly Medicure (NSE:POLYMED) Can Manage Its Debt Responsibly

Here's Why We Think Poly Medicure (NSE:POLYMED) Is Well Worth Watching

Jul 13
Here's Why We Think Poly Medicure (NSE:POLYMED) Is Well Worth Watching

Poly Medicure (NSE:POLYMED) Is Reinvesting At Lower Rates Of Return

Jun 16
Poly Medicure (NSE:POLYMED) Is Reinvesting At Lower Rates Of Return

Be Wary Of Poly Medicure (NSE:POLYMED) And Its Returns On Capital

Mar 02
Be Wary Of Poly Medicure (NSE:POLYMED) And Its Returns On Capital

We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt

Feb 14
We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt

Capital Allocation Trends At Poly Medicure (NSE:POLYMED) Aren't Ideal

Oct 16
Capital Allocation Trends At Poly Medicure (NSE:POLYMED) Aren't Ideal

We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt

Sep 28
We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt

Poly Medicure (NSE:POLYMED) Has Affirmed Its Dividend Of ₹2.50

Sep 08
Poly Medicure (NSE:POLYMED) Has Affirmed Its Dividend Of ₹2.50

Here's Why Poly Medicure (NSE:POLYMED) Can Manage Its Debt Responsibly

Jun 25
Here's Why Poly Medicure (NSE:POLYMED) Can Manage Its Debt Responsibly

A Look At The Intrinsic Value Of Poly Medicure Limited (NSE:POLYMED)

Jun 07
A Look At The Intrinsic Value Of Poly Medicure Limited (NSE:POLYMED)

Poly Medicure (NSE:POLYMED) Will Want To Turn Around Its Return Trends

May 23
Poly Medicure (NSE:POLYMED) Will Want To Turn Around Its Return Trends

With EPS Growth And More, Poly Medicure (NSE:POLYMED) Is Interesting

Feb 23
With EPS Growth And More, Poly Medicure (NSE:POLYMED) Is Interesting

There Are Reasons To Feel Uneasy About Poly Medicure's (NSE:POLYMED) Returns On Capital

Feb 04
There Are Reasons To Feel Uneasy About Poly Medicure's (NSE:POLYMED) Returns On Capital

Poly Medicure (NSE:POLYMED) Seems To Use Debt Quite Sensibly

Jan 12
Poly Medicure (NSE:POLYMED) Seems To Use Debt Quite Sensibly

With EPS Growth And More, Poly Medicure (NSE:POLYMED) Is Interesting

Oct 14
With EPS Growth And More, Poly Medicure (NSE:POLYMED) Is Interesting

Poly Medicure (NSE:POLYMED) Could Easily Take On More Debt

Jul 07
Poly Medicure (NSE:POLYMED) Could Easily Take On More Debt

Poly Medicure (NSE:POLYMED) Will Will Want To Turn Around Its Return Trends

Jun 18
Poly Medicure (NSE:POLYMED) Will Will Want To Turn Around Its Return Trends

CEO報酬分析

Poly Medicure の収益と比較して、Himanshu Baid の報酬はどのように変化したか？
日付総報酬給与会社業績
Sep 30 2024n/an/a

₹3b

Jun 30 2024n/an/a

₹3b

Mar 31 2024₹172m₹58m

₹3b

Dec 31 2023n/an/a

₹2b

Sep 30 2023n/an/a

₹2b

Jun 30 2023n/an/a

₹2b

Mar 31 2023₹130m₹55m

₹2b

Dec 31 2022n/an/a

₹2b

Sep 30 2022n/an/a

₹1b

Jun 30 2022n/an/a

₹1b

Mar 31 2022₹107m₹49m

₹1b

Dec 31 2021n/an/a

₹1b

Sep 30 2021n/an/a

₹1b

Jun 30 2021n/an/a

₹1b

Mar 31 2021₹92m₹44m

₹1b

Dec 31 2020n/an/a

₹1b

Sep 30 2020n/an/a

₹1b

Jun 30 2020n/an/a

₹1b

Mar 31 2020₹62m₹35m

₹959m

Dec 31 2019n/an/a

₹947m

Sep 30 2019n/an/a

₹858m

Jun 30 2019n/an/a

₹719m

Mar 31 2019₹44m₹14m

₹654m

Mar 31 2018₹41m₹14m

₹706m

報酬と市場: Himanshuの 総報酬 ($USD 1.99M ) は、 Indian市場 ($USD 583.85K ) の同規模の企業の平均を上回っています。

報酬と収益: Himanshuの報酬は過去 1 年間で 20% 以上増加しました。

CEO（最高経営責任者

Himanshu Baid (56 yo)

29.3yrs

在職期間

₹171,781,000

報酬

Mr. Himanshu Baid has been the Managing Director of Poly Medicure Limited since September 20, 1995 and serves as Chief Executive Officer. Mr. Baid is an Electronics Engineer and has experience in respect t...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Himanshu Baid
CEO, MD & Director29.3yrs₹171.78m11.59%
₹ 29.5b
Jugal Baid
Founder & Non Executive Directorno data₹1.43m2.25%
₹ 5.7b
Naresh Vijayvergiya
Chief Financial Officer3.5yrs₹11.21mデータなし
Avinash Chandra
Company Secretary & Compliance Officer9.7yrs₹1.88mデータなし
Rishi Baid
Joint MD & Executive Directorno data₹166.82m12.33%
₹ 31.4b
Vishal Baid
President of Corporate Sales & Marketing2.8yrs₹18.39m1.66%
₹ 4.2b
P. Rastogi
Assistant Vice President of Finance & Accountsno dataデータなしデータなし
Hemant Bhalla
Senior Vice President of Domestic Sales & Marketingno data₹5.79mデータなし
Pankaj Gupta
President of R&Dno data₹5.61mデータなし
Manish Sardana
President of Sales & Marketing - Indiano data₹8.61mデータなし

6.6yrs

平均在職期間

56yo

平均年齢

経験豊富な経営陣: POLYMEDの経営陣は経験豊富で経験豊富です（平均在職期間は6.6年）。

取締役

名称ポジション在職期間報酬所有権
Himanshu Baid
CEO, MD & Director29.8yrs₹171.78m11.59%
₹ 29.5b
Jugal Baid
Founder & Non Executive Director29.8yrs₹1.43m2.25%
₹ 5.7b
Rishi Baid
Joint MD & Executive Director29.8yrs₹166.82m12.33%
₹ 31.4b
Vimal Bhandari
Non-Executive Independent Directorless than a yearデータなしデータなし
Amit Khosla
Non-Executive Independent Director4.6yrs₹1.60mデータなし
Devendra Mehta
Non-Executive Independent Chairman19.7yrs₹1.63mデータなし
Mukulika Baid
Non-Executive Director10.5yrs₹1.43m3.02%
₹ 7.7b
Sonal Mattoo
Non-Executive Independent Director4.4yrs₹1.45mデータなし
Alessandro Balboni
Non-Executive Non Independent Director6.7yrs₹29.90mデータなし
Ambrish Mithal
Independent Director2.8yrs₹1.45mデータなし

8.6yrs

平均在職期間

64.5yo

平均年齢

経験豊富なボード: POLYMEDの 取締役会 は 経験豊富 であると考えられます ( 8.6年の平均在任期間)。

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2025/01/20 16:49
終値2025/01/20 00:00
収益2024/09/30
年間収益2024/03/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を例とし、非米国証券については同等の規制書式と情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Poly Medicure Limited 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。11

アナリスト機関
Nitin BhasinAmbit Capital
Karan KhannaAmbit Capital
Sunita VaidyanathanBrics Securities Limited